Introduction
Magnesium sulfate (MgSO 4 ) is a drug that has garnered some interest within the epilepsy community [1] . Whether administered orally, or intravenous (IV), MgSO 4 has displayed some efficacy in the animal and human seizure literature [1, 2] .
Though its mechanism of action as an anti-epileptic drug (AED) is not well understood, it is believe to derive its anti-epileptic properties from N-methyl D-aspartate (NMDA) receptor inhibition. To date, a few animal models support this concept [3] [4] [5] [6] .
Clinically, MgSO 4 has seen much attention within the obstetrics literature as an effective prophylactic and therapeutic agent for pre-eclampsia and eclampsia, respectively [7] . Furthermore, the lack of significant side effects is appealing due to concerns about fetal toxicity. The efficacy of MgSO 4 as an AED in the setting of eclampsia is well documented since the early 1900s, with the mechanism of action attributed to both NMDA receptor antagonism and cerebral vasodilation. In addition, systematic reviews have demonstrated the superiority of MgSO 4 over diazepam, phenytoin and lytic cocktails in the setting of eclampsia [8] [9] [10] .
During status epilepticus (SE) and refractory status epilepticus (RSE) the NMDA receptor plays a key role in pharmaco-resistance and epileptigenicity. As seizures remain uncontrolled, there is an up-regulation of the NMDA receptor, leading to a glutamate mediated excitotoxicity and seizure potentiation [11, 12] . This has lead to the interest in NMDA receptor antagonists as AED in the setting of SE/RSE. Ketamine is an example of one such drug which has displayed some efficacy in this setting [13] .
The use of MgSO 4 in the setting of non-eclamptic SE/RSE has been mentioned in protocols and reviews of therapies [14] [15] [16] . To date however there are only a small number of cases describing the use of IV MgSO 4 for non-eclamptic SE/RSE .
Our goal was to perform a systematic review of the literature on the use of IV MgSO 4 , a NMDA receptor antagonist, for noneclamptic SE/RSE.
Materials and methods
A systematic review using the methodology outlined in the Cochrane Handbook for Systematic Reviewers [39] was conducted. The data was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [40] . The review questions and search strategy were decided upon by the primary author and supervisor.
Search question, population, inclusion and exclusion criteria
The question posed for systematic review was: What is the effectiveness of IV MgSO 4 for non-eclamptic SE/RSE? The definition of SE and RSE was as per the Neurocritical Care Society guidelines on the management of SE [41] . The definition for RSE was as follows: any patient(s) whom continue to experience either clinical or electro-graphic seizures after receiving adequate doses of an initial benzodiazepine followed by a second acceptable antiepileptic drug (AED) will be considered refractory [41] . Non-eclamptic SE was defined as SE in the absence of pregnancy, or SE in the setting of pregnancy but in the absence of the other features of eclampsia such as hypertension and multi-organ dysfunction. The term generalized refractory status epilepticus (GRSE) was used to refer to generalized tonic-clonic RSE. The term focal refractory status epilepticus (FRSE) was used to refer focal tonic-clonic RSE. The term multi-focal refractory status epilepticus (MFRSE) was used to refer to RSE that had a mutli-focal tonic-clonic nature. The term non-convulsive refractory status epilepticus (NCRSE) was used for non-convulsive seizures that fulfilled the criteria for RSE.
All studies, prospective and retrospective of any size based on human subjects were included. The reason for an all-inclusive search was based on the small number of studies of any type identified by the primary author during a preliminary search of MEDLINE.
The primary outcome measure was electrographic seizure control, defined as: complete resolution, partial seizure reduction, and failure. This qualitative seizure response grading was used given the lack of detail around the electroencephalographic response reported within the studies found. Secondary outcome measures were patient outcome (if reported), and adverse effects of the administration of MgSO 4 .
Inclusion criteria were: All studies including human subjects whether prospective or retrospective, all study sizes, any age category, the documented use of IV MgSO 4 for the purpose of seizure control in the setting of SE/RSE, and the absence of preeclampsia/eclampsia as the cause of neurological deterioration or seizures. Exclusion criteria were: animal and non-English studies, treatment with oral MgSO 4 , and any studies describing patients with pre-eclampsia/eclampsia. Finally, reference lists of any review articles or systematic reviews on seizure management were reviewed for relevant studies on MgSO 4 usage for SE/RSE that were missed during the database and meeting proceeding search.
Study selection
Utilizing two reviewers (FZ and MM), a two-step review of all articles returned by our search strategies was performed. First, the reviewers independently screened all titles and abstracts of the returned articles to decide if they met the inclusion criteria. Second, full text of the chosen articles was then assessed to confirm if they met the inclusion criteria and that the primary outcome of seizure control was reported in the study. Any discrepancies between the two reviewers were resolved by a third party (CK).
Data collection
Data was extracted from the selected articles and stored in an electronic database. Data fields included: patient demographics, type of study (prospective or retrospective), number of patients, dose of MgSO 4 used, timing to administration of MgSO 4 , duration of MgSO 4 administration, time to effect of drug, how many other AED were utilized prior to implementation of MgSO 4 , degree of seizure control (as described previously), adverse effects, and patient outcome.
Quality of evidence assessment
Assessment of the level of evidence for each included study was conducted by a panel of two independent reviewers, utilizing the Oxford criteria [42] and the Grading of Recommendation Assessment Development and Education (GRADE) criteria [43] [44] [45] [46] [47] [48] for level of evidence. We elected on utilizing two different systems to grade level of evidence given that these two systems are amongst the most commonly used. We believe this would allow a larger audience to follow our systematic approach in the setting of unfamiliarity with a particular grading system.
The Oxford criteria consist of a 5 level grading system for literature. Level 1 is split into subcategories 1a, 1b, and 1c which represent a systematic review of randomized control trials (RCT) with homogeneity, individual RCT with narrow confidence interval, and all or none studies respectively. Oxford level 2 is split into 2a, 2b, and 2c representing systematic review of cohort studies with homogeneity of data, individual cohort study or low quality RCT, and outcomes research respectively. Oxford level 3 is split into 3a and 3b representing systematic review of case-control studies with homogeneity of data and individual case-control study respectively. Oxford level 4 represents case-series and poor cohort studies. Finally, Oxford level 5 represents expert opinion.
The GRADE level of evidence is split into 4 levels: A, B, C and D. GRADE level A represents high evidence with multiple high quality studies having consistent results. GRADE level B represents moderate evidence with one high quality study, or multiple low quality studies. GRADE level C evidence represents low evidence with one or more studies with severe limitations. Finally, GRADE level D represents very low evidence based on either expert opinion or few studies with severe limitations.
Any discrepancies between the grading of the two reviewers (FZ and MM) were resolved via a third party (CK).
Statistical analysis
A meta-analysis was not performed in this study due to the heterogeneity of data within the articles and the presence of a small number of low quality retrospective studies.
Results
The results of the search strategy across all databases and other sources are summarized in Fig. 1 . Overall a total of 809 articles were identified, with 800 from the database search and 9 from the search of published meeting proceedings. After removing duplicates, there were 599 articles. By applying the inclusion/exclusion criteria to the title and abstract, we identified 47 articles that fit these criteria with 38 from the database search and 9 were from published meeting proceedings. Applying the inclusion/exclusion criteria to the full text documents, only 19 articles were eligible for inclusion in the systematic review, with 10 from database and 9 from meeting proceeding sources. The articles that were excluded were done so because they either did not report details around the administration of IV MgSO 4 for seizure control, or because they were review articles. Reference sections from these review articles were searched for any other articles missed in the database search, with 3 being identified. These were subsequently added to the final group of included articles to make a total of 22 articles for the final review.
Of the 22 articles included in the review , 19 were original studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and 3 were companion publications [36] [37] [38] with duplicate patient data. Madisi et al. [36] and Madisi et al. [37] were meeting proceedings describing the same patient that was eventually described and updated meeting proceeding Berkeley et al. [18] . Similarly, Sahin et al. [38] contained duplicate patient data from 1 of the 2 patients described in Sahin et al. [28] . These three articles [36] [37] [38] were not included in the final data summary in order to prevent duplication of patient data. However, Sahin et al. [38] provided some longer term follow up data on one patient in Sahin et al. [28] , which was included in the outcome data section. All 19 original studies were retrospective studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , with 3 retrospective case series [28, 31, 35] and 16 retrospective case reports [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 29, 30, [32] [33] [34] . All were single center reports. Eleven articles described the use of MgSO 4 in adults [18, 21, [23] [24] [25] [26] 29, 30, 32, 34, 35] . Eight studies described pediatric patients [17, 19, 20, 22, 27, 28, 33, 35] . One study described an adult and pediatric patient [35] . Finally, one study failed to document the age of the patient's treated [31] .
Across all studies, a total of 28 patients were documented as having IV MgSO 4 administered for SE or RSE (mean 1.5 patients/ study; range: 1-8 patients/study). Nine patients were pediatric with a mean age of 11.4 years (age range: 2-17 years). Eleven patients were adult with a mean age of 27.5 years (age range: 18-57 years). Eight patients had no documented age [31] .
Seizures were classified as GSE in 1 patient [27] , GRSE in 13 patients [17, 18, [20] [21] [22] [23] 25, 26, 28, 32, 34, 35] , FRSE in 2 patients [19, 29] , MFRSE in 2 patients [28, 33] , NCRSE in 1 patient [30] , and non defined SE/RSE in 9 patients [24, 31] .
The etiology of SE/RSE varied significantly and were as follows: fever induced refractory epilepsy syndrome (FIRES)/New onset resistant status epilepticus (NORSE) in 3 patients [18, 23, 33] , autoimmune encephalitis in 2 patients [19, 24] , known pre-existing epilepsy in 3 patients [20, 22, 32] , encephalitis in 3 patients [22, 28] , acute intermittent porphyria (AIP) in 1 patient [27] , POLG1 mutation with associated epilepsy in 3 patients [29, 35] , paraneoplastic related in 1 patient [30] , vitamin B6 deficiency in 1 patient [34] , and unknown in 11 patients [17, 25, 26, 31] .
Study demographics and patient characteristics for all studies can be seen in Table 1 , while treatment characteristics and seizure outcome are reported in Table 2 .
MgSO 4 treatment characteristics
Only 7 of the 19 original articles provided [21, 25, 27, 31, [33] [34] [35] details around the treatment parameters for IV MgSO 4 . The remaining 12 studies only referred to the use of MgSO 4 in the management of SE/RSE, without providing any information on dosing [17] [18] [19] [20] [22] [23] [24] 26, [28] [29] [30] 32] .
Four studies [21, 27, 33, 34] described an IV loading dose ranging from 3 to 6 g, followed by a continuous infusion ranging from 0.75 g/h up to 6 g/h. The duration of treatment for these studies varied from 2 to 7 days.
One study described only a continuous infusion of 1 g/h for a 5 day duration [25] . Another study described intermittent bolus dosing of 10 mL of 25% MgSO 4 solution, up to three times [31] . Finally, one study described targeting a serum magnesium concentration of 3.5 mmol/L via an undisclosed MgSO 4 dosing schedule [35] .
Duration of treatment prior to implementation of MgSO 4 therapy was documented in 10 articles [19, [21] [22] [23] 25, 27, 30, 32, 33, 35] , ranging from 3 to 35 days (mean = 19.2 days; median = 19). The remaining 9 articles failed to mention the duration of therapy prior to implementation of MgSO 4 . The number of AEDs administered prior to MgSO 4 therapy was documented in 17 studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [32] [33] [34] [35] , with the total number ranging from 1 to 14 (mean = 7.7, median = 8). Similarly, the duration of MgSO 4 treatment was described in 9 of the 19 studies, with treatment duration ranging from 0.33 h to 7 days (median = 4 days, mean = 4.0 days). Treatment characteristics for the adult studies can be seen in [17] [18] [19] [20] 22, 23, 25, 26, [28] [29] [30] 32, 34] .
Looking at seizure subtype: 3 of the 13 (23.1%) GRSE patients responded, 1 of the 2 (50.0%) MFRSE patients responded, the 1 GSE patient responded, and all 9 (100%) of the ''unknown'' SE/RSE patients responded to IV MgSO 4 therapy. None of the FRSE or NCRSE patients responded to MgSO 4 therapy.
Seizure recurrence upon withdrawal of IV MgSO 4 therapy occurred in 7 of the 14 (50.0%) of those patients whom initially responded.
Adverse effects of MgSO 4
Adverse events related to IV MgSO 4 therapy were documented in 3 patient across 3 studies [21, 27, 32] . One patient developed limb weakness [27] . Two patients developed heart block related to high dose IV MgSO 4 dosing [21, 32] . No cardiac arrest or respiratory complications were reported.
The remaining 16 studies did not document adverse events.
Outcome
Outcome data was poorly recorded in the majority of the studies included within the review. Data on patient outcome was available in only 11 of the 28 (39.3%) of the patients treated [17, 21, 24, 25, 28, 29, 35] . Modified Rankin scores (mRS) were approximated based on the available data within the reports, with mRS scores of 1, 2, 3, 4, 5, or 6 recorded in 2 (18.2%), 2 (18.2%), 0 (0%), 2 (18.2%), 1 (9.1%), and 4 (36.4%), respectively.
No identifiable trend in outcomes could be seen based on seizure subtype, etiology of seizure, or comparing MgSO 4 responders to non-responders.
Level of evidence for MgSO 4
Based on the 19 original articles included in the final review, all fulfill Oxford level 4, GRADE D evidence to suggest some potential impact of IV MgSO 4 on seizure control in the setting of noneclamptic RSE. The role of IV MgSO 4 in the management of noneclamptic SE is unclear.
Summary of the level of evidence can be seen in Table 3 .
Discussion
Given the limited literature to date utilizing IV MgSO 4 therapy in the management of SE/RSE, we decided to perform an extensive systemic review of the literature in order to determine its impact in the setting of non-eclamptic SE/RSE. Through our review we identified 19 original articles [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . A total of 28 patients were described in these articles with 11 being adult, 9 being pediatric, and 8 of unknown age. All studies were retrospective case reports/ series. Seizure reduction/control with IV MgSO 4 occurred in 14 of the 28 patients (50.0%), with 2 (7.1%) and 12 (42.9%) displaying partial and complete responses respectively. Seizures recurred upon withdrawal of MgSO 4 therapy in 50% of the patients whom had reduction/control of their SE/RSE. Three patients had recorded adverse events related to MgSO 4 therapy. Patient outcome data was too sparingly documented for any strong conclusion, with no identifiable trend in outcomes for the responders versus the nonresponders. All studies were an Oxford level 4, GRADE D level of evidence. Thus, based on this review, we can currently provide Oxford level 4, GRADE D recommendations that IV MgSO 4 may provide some impact on seizure control in the setting of noneclamptic SE/RSE.
A few important points can be seen within our review. First, IV MgSO 4 appears moderately effective at impacting seizure control AED, anti-epileptic drug; IV, intravenous; TBI, traumatic brain injury; SE, status epilepticus; RSE, refractory status epilepticus; GSE, generalized status epilepticus; GRSE, generalized refractory status epilepticus; FRSE, focal refractory status epilepticus; MFRSE, multi-focal refractory status epilepticus; NCRSE, non-convulsive refractory status epilepticus; FIRES, fever induced refractory epilepsy syndrome; NORSE, new onset resistant status epilepticus; NMDA, n-methyl d-aspartate; CP, cerebral palsy; hrs, hours. * Berkley et al. [18] , Madisi et al. [36] , and Madisi et al. [37] all contain the same patient data. The data from Berkely et al. [18] was the only data included in the final analysis. ** Sahin et al. [28, 38] report the same patient. The data for this patient was synthesized from both reports, but not duplicated. [36] , and Madisi et al. [37] all contain the same patient data. The data from Berkely et al. [18] was the only data included in the final analysis. ** Sahin et al. [28, 38] report the same patient. The data for this patient was synthesized from both reports, but not duplicated.
in the setting of RSE, with an approximately 50% response rate. However, the exact dosing and duration of IV MgSO 4 in the treatment of non-eclamptic SE/RSE is currently unclear. Second, the anti-epileptic effect of IV MgSO 4 is present even in those cases with RSE exceeding a month or more in duration. Third, 50% of the MgSO 4 responsive patients had recurrence of seizures upon withdrawal of the medication. This highlights that IV MgSO 4 is not a permanent solution to seizure control, but provides an opportunity to titrate other AEDs to effect. It also raises the question as to the utility of transitioning those patients with seizure recurrence to an oral MgSO 4 regimen. Further study is clearly warranted. Finally, only a small number of complications were described, though the cardiac sequelae recorded could potentially have significant consequences for the patient. It is hard to know if the complications described were entirely related to the IV MgSO 4 , or a consequence of multiple drugs and the degree of their critical illness. Regardless, the side effects of hypermagnesemia are important to recognize.
Our review has significant limitations. First, the small number of studies identified, all with small patient populations, makes it difficult to generalize to all non-eclamptic SE/RSE patients. Second, the retrospective heterogeneous nature of the data makes it difficult to perform a meaningful meta-analysis. We are thus left with only descriptive statistics to summarize the available data. Third, the seizure response to IV MgSO 4 may not be related entirely to MgSO 4 at all, and perhaps is a reflection of the combination of multiple AEDs working in concert. The exact dosing and sequence of administration of these AEDs was not clear from the majority of the reports included within this review. Thus, unfortunately we cannot make in depth comments on the impact these regimens may have had on the overall seizure control and response to MgSO 4 . Fourth, our comments on the dosing and treatment regimen for MgSO 4 are limited given the small number of studies and paucity of detail within the articles. Fifth, the potential for publication bias in the articles reviewed is high. It is likely that there are many more negative results with IV MgSO 4 that have not made it to the literature. Similarly, we suspect that the complications of high dose IV MgSO 4 therapy in this context are also under reported. Finally, comments on the impact of IV MgSO 4 on outcome in non-eclamptic SE/RSE are limited. Most studies failed to document outcome and only focused on seizure response.
Currently, the routine use of IV MgSO 4 for seizure control in non-eclamptic SE/RSE cannot be recommended at this time. The results of this review point to a potential impact that this drug may have on seizure control. Further prospective study of the utility of IV MgSO 4 in this context is warranted. There exists a need for international databases that document the impact of therapies in RSE, as they may shed further light on the impact of IV MgSO 4 on seizure control.
Conclusions
Oxford level 4, GRADE D evidence exists to suggest a trend towards improved seizure control with the use of intravenous MgSO 4 for non-eclamptic RSE. Routine use of IV MgSO 4 in noneclamptic SE/RSE cannot be recommended at this time. Further prospective study of this drug is required in order to determine its efficacy as an anti-epileptic in this setting.
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